Please login to the form below

Not currently logged in
Email:
Password:

Merkel cell carcinoma

This page shows the latest Merkel cell carcinoma news and features for those working in and with pharma, biotech and healthcare.

Merck KGaA, Pfizer’s Bavencio improves survival in bladder cancer

Merck KGaA, Pfizer’s Bavencio improves survival in bladder cancer

Bavencio is also approved for the treatment of adults and paediatric patients 12 years and older with metastatic Merkel cell carcinoma, and in combination with tyrosine kinase inhibitor Inlyta (axitinib) as ... a first-line treatment of patients with

Latest news

  • Pfizer poaches cancer R&D head Jeff Settleman from Calico Pfizer poaches cancer R&D head Jeff Settleman from Calico

    That includes Xalkori follow-up Lorbrena (lorlatinib) for ALK-positive non-small cell lung cancer (NSCLC), PARP inhibitor Talzenna (talazoparib) for breast cancer, Daurismo (glasdegib) for acute myeloid leukaemia, and Vizimpro ... Settleman comes in as

  • Merck claims key FDA okay for Bavencio in kidney cancer Merck claims key FDA okay for Bavencio in kidney cancer

    The FDA has just approved Pfizer-partnered Bavencio (avelumab) in combination with Pfizer’s Inlyta (axitinib) as a first-line therapy for patients with advanced renal cell carcinoma (RCC), the most ... For a while, Bavencio is was the only PD-1/PD-L1

  • Vyriad inks immunotherapy alliance with Merck/Pfizer Vyriad inks immunotherapy alliance with Merck/Pfizer

    The drug – sold as Bavencio – has been approved for skin cancer Merkel cell carcinoma and bladder cancer, but in February failed a trial as a second-line therapy for non-small ... cell lung cancer and also had a knockback in third-line stomach cancer

  • Immuno-oncology at ASCO: survival data, combinations and new indications Immuno-oncology at ASCO: survival data, combinations and new indications

    BMS will also present new data on Opdivo in Merkel cell carcinoma and triple-negative breast cancer (TNBC). ... in small-cell lung cancer, gastric or gastroesophageal junction (G/GEJ) cancer and Merkel cell carcinoma.

  • Merck and Pfizer set to win NICE backing for Bavencio Merck and Pfizer set to win NICE backing for Bavencio

    In a final appraisal determination, the UK’s cost-effectiveness body is set to give the drug the all clear to treat patients with previously treated metastatic Merkel Cell Carcinoma (mMCC) ... to access the first targeted systemic treatment option

More from news
Approximately 3 fully matching, plus 21 partially matching documents found.

Latest Intelligence

  • Immuno-oncology in 2019: the rapid evolution continues Immuno-oncology in 2019: the rapid evolution continues

    It sealed its dominance last year with a string of successful endpoint-hitting trials, most especially in non- small cell lung cancer (NSCLC). ... On 28 December, Keytruda gained FDA clearance for use in Merkel cell carcinoma.

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

Latest from PMHub

More from PMHub
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Oxford University Press

Oxford University Press publishes over 100 prestigious, highly cited, and authoritative medical journals, many in collaboration with some of the...

Latest intelligence

Ludovic Helfgott
Novo Nordisk awakens its ‘Sleeping Beauty’
Biopharm emerges from troubled times to hit ‘solid growth’, says executive vice president Ludovic Helfgott...
How will the Tories’ historic win shape the NHS?
Paul Midgley and Oli Hudson, of Wilmington Healthcare, explore the impact of December’s General Election result on 2020 and beyond...
CSR 'Christmas Spirit' 2019
OPEN Health champions CSR over Christmas by giving back to the community and increasing our activities and efforts...

Infographics